Table 3 2009 Price comparison and market share of SEB Epoetins in five European countries [38],[40]
From: Potential impact of subsequent entry biologics in nephrology practice in Canada
| Â | Germany | UK | France | Italy | Spain |
|---|---|---|---|---|---|
Year of 1 st SEB introduced | 2007 | 2008 | 2008 | 2008 | 2009 |
Number of SEB epoetins on market | 4 | 1 | 1 | 3 | 2 |
SEB market share (sales as%) | 53 | 0.95 | 2.97 | 0.29 | 2.91 |
Price innovator vs SEB (€/ddd)* | 9.3 vs. 6.5 | 9.5 vs. 7.8 | 11.4 vs. 7.4 | 9.5 vs.7.8 | 8.5 vs. 6.5 |
Average price difference between innovator epoetin and SEB (%) | 43 | 22 | 54 | 22 | 32 |